Decoy Therapeutics (NASDAQ:DCOY) Shares to Reverse Split on Monday, March 9th

Decoy Therapeutics (NASDAQ:DCOY)’s stock is going to reverse split on Monday, March 9th. The 1-12 reverse split was announced on Thursday, March 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, March 6th.

Decoy Therapeutics Price Performance

Shares of NASDAQ DCOY traded down $0.07 during mid-day trading on Thursday, hitting $0.58. 371,218 shares of the stock traded hands, compared to its average volume of 149,276. Decoy Therapeutics has a twelve month low of $0.51 and a twelve month high of $34.65.

Analyst Upgrades and Downgrades

DCOY has been the topic of several research reports. LADENBURG THALM/SH SH started coverage on Decoy Therapeutics in a report on Friday, January 23rd. They set a “buy” rating and a $2.50 price target on the stock. Weiss Ratings initiated coverage on shares of Decoy Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Finally, Wall Street Zen upgraded shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Decoy Therapeutics currently has an average rating of “Hold” and an average target price of $2.50.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.